LPTX Quote, Financials, Valuation and Earnings

Armata Pharmaceuticals has a net margin of -- compared to Leap Therapeutics's net margin of --. Leap Therapeutics's return on equity of -- beat Armata Pharmaceuticals's return on equity of --.

Leap Therapeutics has a consensus price target of $3.00, signalling upside risk potential of 883.28%. On the other hand Armata Pharmaceuticals has an analysts' consensus of $7.00 which suggests that it could grow by 379.45%. Given that Leap Therapeutics has higher upside potential than Armata Pharmaceuticals, analysts believe Leap Therapeutics is more attractive than Armata Pharmaceuticals.

Leap Therapeutics has a beta of 0.216, which suggesting that the stock is 78.397% less volatile than S&P 500. In comparison Armata Pharmaceuticals has a beta of 0.914, suggesting its less volatile than the S&P 500 by 8.595%.

Leap Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Armata Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Leap Therapeutics pays -- of its earnings as a dividend. Armata Pharmaceuticals pays out -- of its earnings as a dividend.

Leap Therapeutics quarterly revenues are --, which are smaller than Armata Pharmaceuticals quarterly revenues of --. Leap Therapeutics's net income of -$15.4M is lower than Armata Pharmaceuticals's net income of $2.6M. Notably, Leap Therapeutics's price-to-earnings ratio is -- while Armata Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Leap Therapeutics is 7.56x versus 529.20x for Armata Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Perspective Therapeutics has a net margin of -- compared to Leap Therapeutics's net margin of --. Leap Therapeutics's return on equity of -- beat Perspective Therapeutics's return on equity of --.

Leap Therapeutics has a consensus price target of $3.00, signalling upside risk potential of 883.28%. On the other hand Perspective Therapeutics has an analysts' consensus of $15.18 which suggests that it could grow by 612.61%. Given that Leap Therapeutics has higher upside potential than Perspective Therapeutics, analysts believe Leap Therapeutics is more attractive than Perspective Therapeutics.

Leap Therapeutics has a beta of 0.216, which suggesting that the stock is 78.397% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.199, suggesting its more volatile than the S&P 500 by 19.866%.

Leap Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Leap Therapeutics pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

Leap Therapeutics quarterly revenues are --, which are smaller than Perspective Therapeutics quarterly revenues of --. Leap Therapeutics's net income of -$15.4M is higher than Perspective Therapeutics's net income of -$40.2M. Notably, Leap Therapeutics's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Leap Therapeutics is 7.56x versus 13.79x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Electromed has a net margin of -- compared to Leap Therapeutics's net margin of 12.11%. Leap Therapeutics's return on equity of -- beat Electromed's return on equity of 15.91%.

Leap Therapeutics has a consensus price target of $3.00, signalling upside risk potential of 883.28%. On the other hand Electromed has an analysts' consensus of $37.00 which suggests that it could grow by 55.07%. Given that Leap Therapeutics has higher upside potential than Electromed, analysts believe Leap Therapeutics is more attractive than Electromed.

Leap Therapeutics has a beta of 0.216, which suggesting that the stock is 78.397% less volatile than S&P 500. In comparison Electromed has a beta of 0.594, suggesting its less volatile than the S&P 500 by 40.575%.

Leap Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Leap Therapeutics pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

Leap Therapeutics quarterly revenues are --, which are smaller than Electromed quarterly revenues of $16.3M. Leap Therapeutics's net income of -$15.4M is lower than Electromed's net income of $2M. Notably, Leap Therapeutics's price-to-earnings ratio is -- while Electromed's PE ratio is 31.81x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Leap Therapeutics is 7.56x versus 3.58x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

Protalix BioTherapeutics has a net margin of -- compared to Leap Therapeutics's net margin of 35.65%. Leap Therapeutics's return on equity of -- beat Protalix BioTherapeutics's return on equity of 8.75%.

Leap Therapeutics has a consensus price target of $3.00, signalling upside risk potential of 883.28%. On the other hand Protalix BioTherapeutics has an analysts' consensus of $14.50 which suggests that it could grow by 466.41%. Given that Leap Therapeutics has higher upside potential than Protalix BioTherapeutics, analysts believe Leap Therapeutics is more attractive than Protalix BioTherapeutics.

Leap Therapeutics has a beta of 0.216, which suggesting that the stock is 78.397% less volatile than S&P 500. In comparison Protalix BioTherapeutics has a beta of 0.456, suggesting its less volatile than the S&P 500 by 54.351%.

Leap Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix BioTherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Leap Therapeutics pays -- of its earnings as a dividend. Protalix BioTherapeutics pays out -- of its earnings as a dividend.

Leap Therapeutics quarterly revenues are --, which are smaller than Protalix BioTherapeutics quarterly revenues of $18.2M. Leap Therapeutics's net income of -$15.4M is lower than Protalix BioTherapeutics's net income of $6.5M. Notably, Leap Therapeutics's price-to-earnings ratio is -- while Protalix BioTherapeutics's PE ratio is 85.33x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Leap Therapeutics is 7.56x versus 3.98x for Protalix BioTherapeutics. Usually stocks with elevated PS ratios are considered overvalued.